Provided by Tiger Fintech (Singapore) Pte. Ltd.

Galapagos NV

26.86
+0.37001.40%
Pre-market: 27.440.5800+2.16%05:27 EDT
Volume:384.34K
Turnover:10.29M
Market Cap:1.77B
PE:-9.66
High:26.98
Open:26.62
Low:26.50
Close:26.49
Loading ...

Galapagos NV (GLPG): A Cheap Biotech Stock to Invest In Now

Insider Monkey
·
12 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
12 Feb

Galapagos NV expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
10 Feb

Galapagos (GLPG) Loses -21.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
05 Feb

Analysts Offer Insights on Healthcare Companies: Stevanato Group (STVN), Galapagos (GLPG) and Pharvaris (PHVS)

TIPRANKS
·
27 Jan

Morgan Stanley Sticks to Its Hold Rating for Galapagos (GLPG)

TIPRANKS
·
27 Jan

Galapagos Cut to Underweight From Equal-Weight by Barclays

Dow Jones
·
23 Jan

Galapagos downgraded to Underweight from Equal Weight at Barclays

TIPRANKS
·
23 Jan

Morgan Stanley Sticks to Their Hold Rating for Galapagos (GLPG)

TIPRANKS
·
13 Jan

Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%

MT Newswires Live
·
08 Jan

Galapagos announces intention to separate into two publicly traded companies

TIPRANKS
·
08 Jan

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

GlobeNewswire
·
08 Jan

Morgan Stanley Sticks to Its Hold Rating for Galapagos (GLPG)

TIPRANKS
·
23 Dec 2024

Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%

Simply Wall St.
·
13 Dec 2024

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

GlobeNewswire
·
08 Dec 2024

Morgan Stanley Remains a Hold on Galapagos (GLPG)

TIPRANKS
·
25 Nov 2024

Galapagos downgraded to Reduce from Hold at Kepler Cheuvreux

TIPRANKS
·
20 Nov 2024

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

GlobeNewswire
·
06 Nov 2024

Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023)

Simply Wall St.
·
02 Nov 2024

Galapagos Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
02 Nov 2024